Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc (GRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the...

GRTX : 1.2900 (-0.77%)
Galera to Present at Jefferies Healthcare Conference

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 1.2900 (-0.77%)
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and...

GRTX : 1.2900 (-0.77%)
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 ...

GRTX : 1.2900 (-0.77%)
Galera Announces Plan to Submit Avasopasem NDA by Year End

After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of...

GRTX : 1.2900 (-0.77%)
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 1.2900 (-0.77%)
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study

Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

VYGR : 6.08 (+2.88%)
EDIT : 12.59 (+6.42%)
APLT : 0.8650 (-8.77%)
GRTX : 1.2900 (-0.77%)
Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

VYGR : 6.08 (+2.88%)
APTX : 0.5500 (-1.42%)
APLT : 0.8650 (-8.77%)
GRTX : 1.2900 (-0.77%)
Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi

The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.

BMY : 76.84 (-0.21%)
VYGR : 6.08 (+2.88%)
APLT : 0.8650 (-8.77%)
GRTX : 1.2900 (-0.77%)
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA...

GRTX : 1.2900 (-0.77%)

Barchart Exclusives

2 BDC Stocks Yield Over 10% With Excellent Covered Call Plays
These 2 business development companies (BDCs) yield over 10%, even before some extra quarterly dividends they have been issuing. In addition, they off excellent covered call opportunities for investors. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar